Withdraw all COX-2-selective drugs

• 1 Department of General Practice, University of Adelaide, 34 Methodist Street, Willunga, SA 5172
• 2 QUMPPRC, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide
• 3 Department of Pharmacology & Therapeutics and Medicine, University of British Columbia, Vancouver, BC, Canada.

---

• 1. Langton PE, Hankey GJ, Eikelboom JW. Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions [editorial]. Med J Aust 2004; 181: 524-525. Previously published online, 26 October 2004. <MJA full text>
• 2. Celecoxib. Annex II: Overall summary of the scientific evaluation of medicinal products containing celecoxib, etoricoxib, parecoxib, rofecoxib, or valdecoxib. London: European Agency for the Evaluation of Medicinal Products, 2004. Available at: www.emea.eu.int/pdfs/human/referral/celecoxib/EN%20Celecoxib.pdf (accessed Nov 2004).
• 3. Wright JM. The double-edged sword of COX-2 selective NSAIDs. Can Med Assoc J 2002; 167: 1131-1137.
• 4. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709-1711.
• 5. Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum 2002; 47: 349-355.
• 6. Bassett K, Wright JM, Puil L, et al. Cyclooxygenase-2 inhibitor update: journal articles fail to tell the full story. Can Fam Physician 2002; 48: 1455-1460.